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Abstract
Sorafenib—a broad kinase inhibitor—is a standard therapy for advanced hepatocellular carcinoma
(HCC), and has been shown to exert anti-fibrotic effects in liver cirrhosis, a precursor of HCC.
However, the effects of sorafenib on tumor desmoplasia—and its consequences on treatment
resistance — remain unknown. We demonstrate that sorafenib has differential effects on tumor
fibrosis versus liver fibrosis in orthotopic models of HCC in mice. Sorafenib intensifies tumor
hypoxia, which increases stromal-derived factor 1α (SDF1α) expression in cancer and stromal
cells, and subsequently Gr-1+ myeloid cell infiltration. The SDF1α/CXCR4 pathway directly
promotes hepatic stellate cell (HSC) differentiation and activation via MAP kinase pathway. This
is consistent with the association between SDF1α expression with fibrotic septa in cirrhotic liver
tissues as well as with desmoplastic regions of human HCC samples. We demonstrate that after
treatment with sorafenib, SDF1α increased the survival of HSCs and their α-SMA and Collagen I
expression, thus increasing tumor fibrosis. Finally, we show that Gr-1+ myeloid cells mediate
HSC differentiation/activation in a paracrine manner. CXCR4 inhibition using AMD3100 in
combination with sorafenib treatment prevents the increase in tumor fibrosis—despite persistently
elevated hypoxia—in part by reducing Gr-1+ myeloid cell infiltration, and inhibits HCC growth.
Similarly, antibody blockade of Gr-1 reduces tumor fibrosis and inhibited HCC growth when
combined with sorafenib treatment.
Conclusion—Blocking SDF1α/CXCR4 or Gr-1+ myeloid cell infiltration may reduce hypoxia-
mediated HCC desmoplasia and increase the efficacy of sorafenib treatment.
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INTRODUCTORY STATEMENT
Hepatocellular carcinoma (HCC) almost exclusively arises in cirrhotic livers, and the
preexisting chronic inflammation and fibrosis fuel hepatocarcinogenesis and HCC growth
(1–3). Fibrosis is the consequence of hepatic stellate cell (HSC) activation and proliferation,
and myofibroblast differentiation leading to increased collagen deposition (4). This dual
pathology of the liver contributes to an aggressive and systemic treatment-refractory
characteristic in HCCs (1). Recently, the tyrosine kinase inhibitor (TKI) sorafenib has
emerged as the first systemic therapy for HCC. Sorafenib is an antiangiogenic drug that has
a broad tyrosine kinase inhibition spectrum (5). However, despite this progress, the mortality
rate from HCC remains high, making this disease the third leading cause of cancer-related
death worldwide (6–10).
Sorafenib is widely considered as an anti-angiogenic/anti-vascular drug through inhibition
of VEGF receptors (VEGFRs) and platelet-derived growth factor receptors (PDGFRs).
However, more potent and selective anti-VEGF agents or more broad antiangiogenic agents
(e.g., VEGFR/FGFR and anti-VEGFR/PDGFR inhibitors) have failed so far to match the
efficacy of sorafenib in phase III trials in HCC (10–13). Moreover, anti-angiogenic therapy
has not led to tumor regression in patients or in experimental models in mice: The benefit
seen with sorafenib in HCC patients is likely due to a transient delay in HCC growth, after
which most tumors resume their growth (10). Whereas the mechanisms of acquired
resistance to sorafenib and other anti-VEGF inhibitors in HCC remain unknown, it is likely
that tumor stroma-mediated survival pathways might play a key role (1, 10). Of these,
increased hypoxia has been proposed as a mechanism of resistance to multitargeted TKI
therapy (14–17). The challenge is to identify the key molecular pathways regulating stroma-
mediated resistance to sorafenib treatment in HCC.
Hypoxia and other cellular stresses can promote the expression of the chemokine stromal-
derived factor 1 alpha (SDF1α or CXCL12) and of its receptor CXCR4 (18–22). In clinical
studies, we showed that SDF1α level increased in plasma circulation in HCC patients after
treatment with sunitinib or cediranib (both anti-VEGFR and anti-PDGFR TKIs) (23, 24).
Moreover, we showed that elevated circulating levels of SDF1α correlated with poor
treatment outcome in HCC patients after sunitinib treatment (23). Systemic activation of
SDF1α/CXCR4 axis is known to mediate intra-tumoral infiltration of inflammatory cells,
including Gr-1+ myeloid (CD11b+) cells (25–28). Gr-1+ myeloid cells can drive tumor
recurrence after anti-VEGF therapy in various tumor models (29). Finally, clinical
correlative data also strongly suggest that the effects on multi-targeted TKI treatment on
tumor vasculature and on myeloid cells may mediate the response and resistance therapy in
HCC patients (23, 30). However, a causal role of Gr-1+ myeloid cells in HCC resistance to
anti-angiogenic treatment has not been characterized. Furthermore, a mechanistic
understanding of the interplay between treatment-induced hypoxia, SDF1α/CXCR4 pathway
activation, and Gr-1+ myeloid cell infiltration and tumor fibrosis in HCC is currently
lacking. Here, we examined in orthotopic HCC models whether the SDF1α/CXCR4
pathway is activated and causally related to Gr-1+ myeloid cell infiltration and tumor-
associated fibrosis and, ultimately, to sorafenib resistance.
Chen et al. Page 2
Hepatology. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
EXPERIMENTAL PROCEDURES
Cells and Materials
We used the C3H mouse-derived HCC cell line HCA-1 (31). Human hepatic stellate cells
(HSCs; Catalog #5300) were purchased from ScienCell Research Laboratories (San Diego,
CA). These primary HSCs have been previously characterized (32). We purchased
AMD3100 and FR180204 from Sigma (St. Louis, MO), AZD6244 and sorafenib from
Selleck Chemicals (Houston, TX), recombinant PDGF-B and SDF1α from R&D system
(Minneapolis, MN), and anti-Gr-1 antibody (LeafTH purified anti-mouse Gr-1 antibody)
from Biolegend (San Diego, CA). For co-culture experiments, we isolated Gr-1+ myeloid
cells from enzymatically digested HCA-1 tumors.
Animals
To induce liver fibrosis, we treated 5-week-old male C3H or Mst1−/−Mst2F/− mice with
carbon tetrachloride (CCl4, 16 %v/v in olive oil, 100μL gavage, 3 times per week) prior to
tumor implantation/induction. HCA-1 cells were orthotopically implanted in mice 2 weeks
after the last CCl4 treatment, as previously described (33). Mst1−/−Mst2F/− mice develop
spontaneous HCCs after i.v. injection of Ad-Cre (34), and were a kind gift from Dr. Nabeel
Bardeesy (MGH). All animals received humane care according to the criteria outlined in the
“Guide for the Care and Use of Laboratory Animals” prepared by the National Academy of
Sciences and published by the National Institutes of Health (NIH publication 86–23 revised
1985).
Treatment studies
Mice were treated daily by gavage with sorafenib (40mg/kg) or vehicle (PBS) alone.
AMD3100 (10mg/kg/day) was delivered continuously using Alzet micro-osmotic pumps
(DURECT Corporation, Cupertino, CA) over 2 weeks.
Cell viability assays
We assessed cell viability using 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium
bromide (MTT) assay (Sigma).
Western blot analysis
Western blotting was performed using antibodies against collagen I and α-SMA (Abcam,
Cambridge, MA), and phosphorylated (p)-ERK, ERK, p-AKT and AKT (Cell Signaling,
Danvers, MA).
siRNA knockdown
ON-TARGETplus CXCR4 siRNA and non-targeting control siRNA were purchased from
Dharmacon (Lafayette, CO) and used for transfection of HCA-1 cells.
Immunohistochemistry
For murine samples, we used antibodies against α-SMA, CAIX (Abcam), collagen I (LF-67,
kindly provided by Dr. L. Fisher, National Institute of Dental Research), and SDF1α
(BioVision). For apoptosis detection, frozen tumor sections were stained using TACS™ TdT
Kit (R&D Systems, Minneapolis, MN). To assess expression level, we measured the
fluorescently stained area for each marker and normalized it to DAPI area (used as measure
of cellularity in viable tumor regions), as previously described (28). In addition, we
performed immunostaining for SDF1α in tumor samples from patients who underwent HCC
resection. Hepatic fibrosis in the non-HCC liver area was evaluated according to the
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Laennec system as previously described (35). Co-localization between SDF1α expression
and desmoplasia was assessed in 10 randomly selected high-power fields at 4x
magnification.
Flow cytometry
We used fluorescently labeled rat monoclonal antibodies anti-mouse CD45-PE-Cy7, Gr-1-
APC and CD11b-APC-Cy7 (BD Biosciences) to perform flow cytometric analysis in
digested tumor tissue, as previously described (36).
Quantitative RT-PCR
We determined the relative gene expression of SDF1α, CXCR4, MCP-1, 5-LO, TGF-α,
TGF-β, PDGF-α, PDGF-β, MMP9, MMP13, and β-actin in tumor-infiltrating Gr-1+ cells
using specific primers (Table S1), Real-Time SYBR Green PCR master mix (Applied
Biosystems, Branchburg, NJ) and the Stratagene Mx3000P QPCR System, as previously
described (36).
Statistical analysis
Comparisons between treatment groups were performed using the Mann-Whitney U-test. A
p-value of less than 0.05 was considered to denote statistical significance. (See more details
in Supplemental Experimental Methods.)
RESULTS
Sorafenib treatment increases hypoxia and SDF1α expression in orthotopic HCC models
To model the clinical features of HCC, we first induced liver fibrosis in mice by CCl4
treatment for 11 weeks (Fig. S1). Then, we generated orthotopic tumors by intrahepatic
HCA-1 cell implantation in C3H mice or by inducing spontaneous HCC using Cre-
adenovirus (Ad-Cre) i.v. injection in Mst1−/− Mst2F/− mice (Fig. S2). When tumors became
established, we treated the mice with sorafenib for 14 days and then measured the changes
in tissue oxygenation. Sorafenib treatment significantly increased the hypoxic tissue fraction
—measured by carbonic anhydrase IX (CAIX) immunostaining—when compared to
control-treated tumors (Fig. 1A, B). In contrast, hypoxic tissue surface area did not increase
in the surrounding fibrotic liver tissue after treatment (Fig. 1E).
To examine the consequence of treatment-induced increase in tumor hypoxia, we next
evaluated whether the increase in SDF1α expression—suggested by studies in HCC patients
(23, 24)—is recapitulated in these HCC models. Indeed, we found a 2-fold elevation in
SDF1α expression after sorafenib treatment in HCA-1 tumor grafts and in spontaneous
HCCs in Mst1−/− Mst2F/− mice (Fig. 1A–D, Fig. S3). In contrast, SDF1α expression did not
significantly increase in the fibrotic liver after sorafenib treatment (Fig. 1F).
To confirm that hypoxia is the driver of SDF1α expression in cancer and stromal cells, we
cultured HCA-1 cells as well as hepatic stellate cells (HSCs) for 48hr in hypoxic (1% O2) or
normoxic (21% O2) conditions and measured SDF1α expression by qPCR. Exposure to
hypoxic conditions increased SDF1α expression in both HCC cells and HSCs (Fig. S4).
To evaluate the effect of SDF1α/CXCR4 pathway inhibition on tumor tissue oxygenation
and SDF1α expression after treatment, we combined sorafenib treatment with the CXCR4
inhibitor AMD3100 (Sigma, 10mg/kg/day). Interestingly, the combination therapy further
increased hypoxic tissue fraction and SDF1α expression in orthotopic HCA-1 tumor grafts
and spontaneous HCCs in Mst1−/− Mst2F/− mice when compared to sorafenib treatment
alone (Fig. 1, Fig. S3).
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Inhibition of CXCR4 prevents the increase in HCC fibrosis after sorafenib in vivo
To establish if fibrosis is associated with elevated SDF1α expression in HCC patients, we
examined surgical specimens for HCC patients with cirrhosis. We observed that SDF1α
expression co-localized with extracellular matrix components/fibrotic septa in both HCC
and cirrhotic liver tissues (Fig. 2). Thus, we next evaluated the effect of sorafenib treatment
with or without the inhibition of SDF1α/CXCR4 pathway on fibrosis, a hallmark of HCC
progression (4), in the mouse models. To this end, we measured the expression of collagen I
as well as the number of α SMA+ myofibroblasts after sorafenib treatment both in the tumor
region and in the surrounding liver tissue. Of note, the α SMA+ myofibroblasts were also
positive for GFAP (Fig. S5). IHC analyses revealed that the HCCs growing in the face of
sorafenib treatment showed significantly increased tumor desmoplasia. Treatment resulted
in increased intra- and peri-tumoral collagen I and α-SMA+ myofibroblasts infiltration in
orthotopic HCA-1 HCCs in mice with CCl4-induced liver fibrosis and in spontaneous HCCs
in Mst1−/− Mst2F/− mice (Fig. 3A–E). Of note, sorafenib treatment reduced collagen I
expression levels in the surrounding liver tissue in mice with CCl4-induced liver fibrosis
(Fig. 3F).
To assess the effect of SDF1α/CXCR4 pathway inhibition on tumor-associated fibrosis after
sorafenib treatment, we tested the combined administration of sorafenib with the CXCR4
inhibitor AMD3100. This combination therapy prevented the increase in collagen I
expression and α SMA+ myofibroblasts after sorafenib treatment in spontaneous and
implanted HCCs, without significantly changing collagen I expression in the fibrotic liver in
CCl4-treated mice (Fig. 3). Of note, this effect was seen despite a persistent increase in
hypoxia and SDF1α expression in the HCCs treated with sorafenib and AMD3100 (Fig.
1A–D). Thus, CXCR4 inhibition can prevent the pro-fibrotic effects of sorafenib treatment
in HCC in vivo, despite persistent tumor hypoxia.
SDF-1α/CXCR4 axis directly mediates hepatic stellate cell (HSC) differentiation to
myofibroblasts in HCC despite PDGFR blockade by sorafenib
We next examined the role of SDF1α/CXCR4 axis in selective promotion of tumor fibrosis
after sorafenib treatment in vitro. To determine if increased SDF1α expression in the tumor
could mediate the increase in tumor fibrosis after sorafenib treatment, we first exposed
primary HSCs to recombinant (r)SDF1α in the presence or absence of sorafenib or rPDGF-
B. Consistent with previous reports (37), we found that rPDGF-B stimulated proliferation
and α-SMA expression in HSCs (Fig. 4A, B). Sorafenib treatment prevented the effects of
rPDGF-B and led to significant decrease in HSC viability (as evidenced by an increase in
cleaved caspase 3 expression and in the number of apoptotic HSCs) and inhibited α-SMA
and collagen I expression (Fig. 4A–C). These results indicate that sorafenib treatment may
directly reduce liver fibrosis by blocking PDGFR pathway in HSCs. Exposure to rSDF1α
induced HSC differentiation into myofibroblast, as evidenced by dose-dependent increases
in α-SMA and collagen I expression as well as in ERK and Akt activation (Fig. 4D). We
then evaluated whether SDF1α can drive HSC differentiation and activation of HSCs in the
face of PDGFR blockade by sorafenib treatment. We found that SDF1α increased cell
proliferation and viability, and promoted the differentiation of HSCs despite sorafenib
treatment (Fig. 4A–C).
Finally, to determine if SDF1α/CXCR4 axis mediates these effects in HSCs, we used
pharmacologic and genetic approaches to inhibit CXCR4. To this end, we cultured HSCs in
the presence of rSDF1α with or without the CXCR4 inhibitor AMD3100 or with or without
CXCR4 expression knockdown using siRNA. In both settings, inhibition of CXCR4
prevented the effects of SDF1α on HSC differentiation and activation (i.e., prevented the
increase in α-SMA and collagen I expression induced by SDF1α in HSCs) (Fig. 4D, E, Fig.
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S6). The inhibitory effects were mediated in part by preventing the activation of the MAPK
pathway activation by SDF1α, as shown by ERK inhibition with FR180204 (2μM) or MEK
inhibition with AZD6244 in HSCs treated with rSDF1α (Fig. 4D–F, Fig. S7).
Gr1+ myeloid cell infiltration increases in HCC after sorafenib in an SDF1α/CXCR4
dependent manner
We next examined the effects of treatment with sorafenib—with or without inhibition of
CXCR4—on inflammatory cell infiltration in HCC. To this end, we evaluated enzymatically
digested HCC tissue by flow cytometric analysis. We found that the number of Gr-1+
myeloid cells increased by over 2-fold in HCA-1 transplanted HCC models and in
spontaneous HCCs in Mst1−/− Mst2F/− mice after sorafenib treatment (Fig. 5A, B). In
contrast, we found that sorafenib treatment reduced the accumulation of Gr-1+ myeloid cells
in the surrounding fibrotic liver tissue (Fig. 5C). Finally, inhibition of CXCR4 using
AMD3100 in combination with sorafenib decreased the number of tumor-infiltrating Gr-1+
myeloid cells to levels comparable to control-treated spontaneous and transplanted HCCs
(Fig. 5A–B).
Gr1+ myeloid cell infiltration increases fibrosis in HCC after sorafenib in a SDF1α/CXCR4
dependent manner
We next tested whether direct Gr-1+ myeloid cell blockade could prevent the increase in
fibrosis after sorafenib treatment in HCC. To achieve this, we used an anti-Gr-1-blocking
antibody with or without sorafenib treatment in mice with CCl4-induced liver fibrosis with
orthotopically implanted HCA-1 tumors. Gr-1 blockade prevented the increase in Gr-1+
myeloid cell infiltration in HCC after sorafenib treatment to levels comparable to tumors
from control-treated mice (Fig. 6A). Moreover, inhibition of Gr-1+ myeloid cell infiltration
also prevented the increase in HCC-associated fibrosis seen after sorafenib treatment (i.e.,
decreased the levels of collagen I and α–SMA expression) (Fig. 6B, C). To examine the
mechanisms by which Gr-1+ myeloid cells promote fibrosis, we isolated HCC-infiltrating
Gr-1+ (Ly-6G/Ly-6C) myeloid cells from HCA-1 digested tumor tissue by way of magnetic
separation, and co-cultured them with HSCs – either with or without direct contact. In both
co-culture systems, Gr-1+ cells stimulated collagen I and α–SMA expression (measured in
HSCs) in a dose-dependent manner (Fig. 6D, Fig. S8A). This indicates that soluble factors
released by Gr-1+ myeloid cells promote fibrosis. To determine whether the effects of Gr-1+
myeloid cells on HSCs can overcome the PDGFR blockade by sorafenib, we repeated the
co-culture experiments in the presence or absence of sorafenib and rPDGF-B. We found that
Gr-1+ myeloid cells can drive, in a dose-dependent manner, HSC differentiation and
activation despite effective blockade of PDGFR by sorafenib treatment (Fig. 6E, Fig. S8B).
To examine the pro-fibrotic factors involved in this paracrine interaction, we sorted Gr1+
myeloid cells from digested HCC tissue from mice treated with sorafenib or vehicle control
and then extracted mRNA. We next performed real-time PCR analysis to measure the
expression of pro-fibrotic cytokines (4). Gr-1+ myeloid cells from sorafenib-treated tumors
showed higher expression of several pro-fibrotic factors (5-lipoxygenase (5-LO), PDGF-B
and MCP-1 as well as of SDF1α and CXCR4) compared to Gr-1+ myeloid cells from
control-treated tumors (Table S2). To evaluate if SDF1α/CXCR4 axis mediates not only
Gr-1+ myeloid cell infiltration in HCC but also their paracrine interaction with HSCs
leading to fibrosis, we inhibited CXCR4 with AMD3100 in the co-culture systems described
above. AMD3100 treatment prevented the upregulation of collagen I and α-SMA expression
in HSCs co-cultured with tumor-derived Gr-1+ myeloid cells, in a dose-dependent manner
(Fig. 6F). Taken together, these data show that SDF1α/CXCR4 pathway mediates both the
increased infiltration of Gr-1+ myeloid cells in HCC after by sorafenib treatment as well as
their pro-fibrotic effects on HSCs.
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Inhibition in CXCR4 or Gr-1 in combination with sorafenib inhibits HCC growth compared
to sorafenib alone
Finally, given the SDF1α mediation of pro-fibrotic and pro-inflammatory effects in HCC
after sorafenib treatment, we next evaluated the specific impact of fibrosis on HCC growth
after treatment with sorafenib or the CXCR4 inhibitor AMD3100. First, we found that the
growth of spontaneous and grafted HCC was accelerated in mice with fibrotic liver
compared to mice with normal liver (Fig. 7A, Fig. S2). AMD3100 treatment alone showed
no significant inhibition of HCC growth. However, when combined with sorafenib,
AMD3100 induced a significant additional tumor growth inhibition of orthotopic HCA-1
tumors in immunocompetent C3H mice with underlying liver fibrosis (Fig. 7A). Moreover,
inhibition of CXCR4 with AMD3100 in combination of sorafenib induced a significant
increase in cell apoptosis compared to sorafenib or AMD3100 alone in both grafted and
spontaneous orthotopic HCC models (up to 20% in HCA-1 growing in fibrotic liver) (Fig.
7B–E). Of note, the liver function parameters (ALT, AST and ALP) remained unchanged
after combination treatments (not shown). Finally, combination of anti-Gr-1 antibody with
sorafenib also induced a significant delay in HCC growth compared to sorafenib alone (Fig.
7F).
DISCUSSION
Despite its inhibitory effect on hepatic fibrogenesis, the efficacy of sorafenib treatment in
HCC may be thwarted ensuing increase in hypoxia that leads to increased tumor
desmoplasia and inflammation. We show that although sorafenib can reduce chemically
induced liver fibrosis in mice, its anti-vascular effects in tumors lead to increased hypoxia,
inflammation and fibrosis in the tumor tissue. Our results confirm the anti-fibrotic effects
seen in cirrhotic livers with sorafenib and other TKIs (vatalanib) (38, 39), but also reveal
that tumor-associated fibrosis/desmoplasia is increased after sorafenib treatment. This
indicates a potential role of hypoxia-induced tumor fibrosis during development of
resistance to sorafenib treatment in HCC.
PDGF-B is a pro-fibrotic growth factor whose signaling is blocked by sorafenib (5, 40, 41).
However, the conversion of HSCs to myofibroblasts during hepatic fibrogenesis or the
activation of fibroblasts during development of desmoplasia in malignant tumors (such as
breast cancer) may be directly mediated by other pro-fibrotic and pro-inflammatory factors
such as SDF1α (42–47). We demonstrate here in mouse models of HCC that increased
tumor-associated fibrosis is due to increased myofibroblast infiltration and differentiation
mediated by the SDF1α CXCR4 pathway (Fig. 8). Our data show that SDF1α can directly
induce HSC differentiation and proliferation via MAPK activation after sorafenib treatment.
We also show that SDF1α can counteract the anti-fibrotic effects of sorafenib via PDGFR-
inhibition – thus leading to increased tumor-associated fibrosis. This led us to test whether
CXCR4 blockade could prevent the increase in fibrosis in HCC after sorafenib treatment.
Indeed, addition of CXCR4 to sorafenib treatment prevented the increase in tumor-
associated fibrosis in the face of persistent hypoxia. Moreover, this combination therapy
significantly inhibited HCC growth compared to sorafenib alone.
Increased SDF1α expression can also lead to accumulation of tumor-promoting (pro-
angiogenic and immune-suppressive) inflammatory cells (18, 25, 48, 49). We previously
demonstrated that CXCR4 is critical for myeloid cell infiltration in tumors and can
compensate for VEGFR1 inhibition in bone marrow-derived cells by inhibiting CXCR4 with
pharmacologic agents and in genetic models (28). Indeed, we detected an increased
infiltration in Gr-1+ myeloid cells in HCC after sorafenib treatment. Paracrine interactions
between stellate cells and inflammatory cells leading to liver fibrosis are also critical in viral
hepatitis and in pancreatic malignancies (43–45, 50). Here, we demonstrate that Gr-1+
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myeloid cells from sorafenib-treated tumors showed higher expression of multiple pro-
fibrotic factors, including SDF1α and CXCR4, compared to Gr-1+ myeloid cells from
control-treated tumors. Furthermore, we show Gr-1+ cells directly stimulated the
differentiation of HSCs and the CXCR4 blockade prevented the upregulation of collagen I
and α-SMA expression in HSCs co-cultured with tumor-derived Gr-1+ myeloid cells. It
indicates that SDF1α/CXCR4 axis plays an important role mediating not only Gr-1+
myeloid cell infiltration in HCC but also their paracrine interaction with HSCs leading to
fibrosis. Finally, antibody blockade of Gr-1 reduced Gr-1+ myeloid cell infiltration, tumor
desmoplasia, and HCC growth.
In conclusion, targeting the SDF1α/CXCR4 pathway or Gr-1+ myeloid cell infiltration may
be an effective approach to block hypoxia-induced HCC desmoplasia and overcome
resistance to sorafenib therapy in HCC.
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Figure 1. Tumor hypoxia and SDF1α expression are increased after sorafenib treatment in
orthotopic HCC
A, Representative immunofluorescence staining of CAIX and SDF1α in HCA-1 tumor
implanted in mice with liver fibrosis. Images are 636μm across. B,C, The hypoxic tumor
tissue fraction (B) and SDF1α expression (C) increased significantly after sorafenib
treatment in orthotopic HCA-1 tumors in mice (n=5–9). D, Immunofluorescence imaging
analysis showed that SDF1α expression is increased after 14 days of sorafenib treatment in
spontaneous HCCs in Mst1−/− Mst2F/− transgenic mice. The increased hypoxia and SDF1α
expression persisted when sorafenib treatment was combined with AMD3100 (n=5–9). E,F,
Expression of CAIX (E) and SDF1α (F) in the liver was not significantly changed after
sorafenib, AMD3100 or combination treatment (n=4–7). The number of random regions of
interest used for quantification is shown in parentheses. Data are presented as mean ± SEM;
*P<0.05, **P<0.01.
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Figure 2. Immunostaining for SDF1α in liver tissue samples from HCC patients
Paraffin embedded tissue sections were stained for SDF1α by immunohistochemistry. A,B
SDF1α expression in non-malignant liver tissue (A) was consistently lower than in
malignant HCC tumor area (B). Both in cirrhotic liver tissue (C) and in HCC nodules (D),
SDF1α expression was colocalized with ECM components/fibrous septa supporting the
potential pro-fibrotic role of SDF1α in human hepatic fibrogenesis and HCC desmoplasia.
E, Specimens of tumors that re-occurred after transcatheter arterial chemoembolization and
radiofrequency ablation – both of which are known to cause severe hypoxia – consistently
showed high expression of SDF1α, which was also associated with more pronounced
desmoplasia in HCC area. Error bars represent score ± SEM (n=10 regions of interest per
sample).
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Figure 3. Sorafenib treatment selectively increases tumor-associated fibrosis in HCC in an
SDF1α/CXCR4 pathway-dependent manner
A,B, Sorafenib significantly increased the collagen I content (A) and the number of α-SMA+
myofibroblasts (B) in orthotopic HCA-1 tumors implanted in mice with fibrotic livers. The
analysis was performed using immunofluorescence in tumor tissue, and maker-positive area
was normalized to the area of DAPI (nuclear stain) (N=5–7). C–D, Sorafenib treatment
significantly increased the collagen I content (C and D) and the expression of α-SMA (D)
(detected by Western blotting) in spontaneously arising HCCs (N=7–8). E, Representative
images of immunofluorescence of Collagen I staining in spontaneous HCCs. Images are
636μm across. Addition of AMD3100 to sorafenib treatment prevented the increase in
collagen I content and the number of α-SMA+ myofibroblasts in HCCs (A–E). F, In tumor-
bearing mice, sorafenib significantly reduced the collagen I content in the surrounding liver
tissue in mice with underlying liver fibrosis to levels comparable to those seen in livers from
non-CCl4-treated mice (N=4–8). The number of random regions of interest used for
quantification is shown in parentheses. *p<0.05; **p<0.01; Data are shown as mean ± SEM.
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Figure 4. SDF1α/CXCR4 axis promotes HSC to myofibroblast differentiation in the face of
PDGFR blockade by sorafenib
A, Exposure to recombinant PDGF-B increased HSC proliferation, while treatment with
sorafenib reduced the viability of HSCs. Exposure to recombinant SDF1α increased the
viability of HSCs despite PDGFR inhibition using sorafenib treatment, in a dose-dependent
manner. HSC viability was measured by MTT assay (N=6 experimental repeats). B,
Exposure to recombinant SDF1α increased the expression of α-SMA and collagen I and
reduced cleaved caspase-3 expression (evaluated by Western blotting) despite sorafenib
treatment, in a dose-dependent manner. C, Exposure to recombinant SDF1α increased
viability of HSCs despite sorafenib treatment (N=3–5 experimental repeats). D, Exposure to
recombinant SDF1α upregulated collagen I and α-SMA expression levels as well as ERK
and AKT activation in HSCs, consistent with their myofibroblast differentiation. Inhibition
of CXCR4 with AMD3100 (D) or using siRNA (E) prevented the effects of SDF1α. F, ERK
inhibition with FR-180204 (2μM) decreased α-SMA expression in HSCs treated with
recombinant SDF1α. Data are presented as mean ± SEM.
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Figure 5. Intratumoral infiltration of Gr1+ myeloid cells is increased after sorafenib (SOR)
treatment, and is prevented by CXCR4 inhibition in HCC
A–B, After SOR treatment, the number of 7AAD–CD11b+Gr1+ monocytes (measured by
flow cytometry) significantly increased in HCA-1 tumors growing C3H mice with liver
fibrosis (A) of as well as in spontaneous HCCs in Mst1−/− Mst2F/− transgenic mice (B).
Treatment with the CXCR4 inhibitor AMD3100 prevented this effect (A–B). C, The number
of 7AAD–CD11b+Gr1+ myeloid cells was significantly reduced in the fibrotic liver tissues
from sorafenib-treated mice. Data are shown as percentages of the total number of cells
evaluated in enzymatically digested tissue. Data are presented as mean ± SEM (N=5–14
mice per group). **P<0.01.
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Figure 6. Gr-1+ myeloid cell infiltration increases fibrosis in HCC after sorafenib in an SDF1α/
CXCR4 pathway-dependent manner
A–C, Depletion of Gr-1+ myeloid cells using systemic therapy with anti-Gr-1 blocking
antibodies prevents the shift towards a pro-fibrotic environment after sorafenib treatment.
Sorafenib significantly increased the number of 7AAD–CD11b+Gr1+ monocytes (A) (N=3–
7 mice per group), the collagen I content (B) and the number of α-SMA+ myofibroblasts (C)
in orthotopic HCA-1 tumors growing in mice with liver fibrosis, evaluated by
immunohistochemistry. Combining anti-Gr-1 antibodies with sorafenib treatment prevented
these effects. Quantification was performed in 5–12 confocal microscopy images per mouse.
D–F, Tumor-infiltrating Gr-1+ myeloid cells directly mediate HSC differentiation to
myofibroblasts via SDF1α/CXCR4 axis. Co-culture with tumor-tissue isolated Gr1+
myeloid cells (obtained using magnetic beads) increased collagen I and α-SMA expression
levels as well as ERK activation in HSCs (D). Co-culture with Gr1+ myeloid cells increased
collagen I and α-SMA expression in HSCs despite sorafenib treatment, in a dose-dependent
manner (E). Recombinant PDGF-B and sorafenib alone were used as positive and negative
control, respectively, for HSC differentiation (E). Inhibition of CXCR4 with AMD3100
prevented the increase in collagen I, α-SMA, and p-ERK expression in HSCs co-cultured
with Gr-1+ myeloid cells (F). Data are presented as mean ± SEM. * P<0.05.
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Figure 7. Sorafenib induces a modest growth delay in HCC, and CXCR4 inhibition or blockade
of Gr-1 synergize with sorafenib treatment by increasing cell apoptosis
A, Sorafenib (SOR) treatment induces a minor but significant delay in orthotopic HCC
models after 14 days of treatment. HCA-1 tumor growth was delayed by sorafenib in
syngeneic C3H mice with underlying liver fibrosis (N=6–14 mice per group). Whereas
treatment with the CXCR4 inhibitor AMD3100 (AMD) had no effect as monotherapy,
AMD3100 with sorafenib induces a more significant tumor growth delay. B, Representative
images of immunofluorescence TUNEL in HCA-1 tumors. Images are 636μm across. C,
Cell apoptosis, measured by TUNEL, increased after sorafenib treatment in HCA-1 tumors
(N=6–11). D, Representative images of immunofluorescence of TUNEL in spontaneous
HCCs. Images are 636μm across. E, Cell apoptosis, measured by TUNEL, increased after
sorafenib treatment in spontaneously arising HCCs in Mst1−/− Mst2F/− transgenic mice
(N=6–11). Cell apoptosis was significantly increased when sorafenib treatment was
combined with AMD3100 in both tumor models. F, Combining anti-Gr-1 antibodies with
sorafenib treatment induced a significant tumor growth delay of orthotopic HCA-1 tumors
growing in mice with liver fibrosis (N=7–13 mice per group). Data are presented as mean ±
SEM; *P<0.05, **P<0.01.
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Figure 8. Differential impact of sorafenib on liver versus tumor-associated fibrosis mediated by
SDF1α/CXCR4 axis and Gr-1+ cells in HCC
The differential effects of sorafenib are the result of increased intratumoral hypoxia, leading
to elevated SDF1α expression and Gr-1+ myeloid cell infiltration. Blocking CXCR4
prevents Gr-1+ myeloid cell infiltration and hepatic stellate cells differentiation and
activation, and synergizes with the anti-tumor effects of sorafenib.
Chen et al. Page 19
Hepatology. Author manuscript; available in PMC 2015 April 01.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
